WO2003006449A1 - Method for the preparation of escitalopram - Google Patents
Method for the preparation of escitalopram Download PDFInfo
- Publication number
- WO2003006449A1 WO2003006449A1 PCT/DK2002/000491 DK0200491W WO03006449A1 WO 2003006449 A1 WO2003006449 A1 WO 2003006449A1 DK 0200491 W DK0200491 W DK 0200491W WO 03006449 A1 WO03006449 A1 WO 03006449A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- group
- compound
- escitalopram
- derivative
- Prior art date
Links
- WOLPGGGWZDXCNM-IBGZPJMESA-N CN(C)CCC[C@@]1(c(cc2)ccc2F)OCc2cc(Br)ccc12 Chemical compound CN(C)CCC[C@@]1(c(cc2)ccc2F)OCc2cc(Br)ccc12 WOLPGGGWZDXCNM-IBGZPJMESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
- C07C215/32—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
Definitions
- the present invention relates to the preparation of the compound escitalopram, which is the S-enantiomer of the well-known antidepressant drug citalopram, i.e. (S)- 1 -[3-(dimethylamino)propyl]- 1 -(4-fluorophenyl)- 1 ,3-dihydro-5-isobenzofuran- carbonitrile, or a pharmaceutically acceptable salt thereof for the preparation of pharmaceutical preparations.
- S S-enantiomer of the well-known antidepressant drug citalopram
- (S)- 1 -[3-(dimethylamino)propyl]- 1 -(4-fluorophenyl)- 1 ,3-dihydro-5-isobenzofuran- carbonitrile or a pharmaceutically acceptable salt thereof for the preparation of pharmaceutical preparations.
- Citalopram is a well-known antidepressant drug that has now been on the market for some years and has the following structure:
- Escitalopram the enantiomers of the diol II and methods for their preparation are disclosed in US Patent No 4,943,590. Two routes to escitalopram are disclosed, both of them are starting with the racemic diol II. In the first route, the diol II is reacted with an enantiomerically pure acid derivative, such as (+) or (-)- ⁇ -methoxy- ⁇ - trifluoromethyl-phenylacetyl chloride to form a mixture of diastereomeric esters, which are separated by HPLC or fractional crystallization, whereupon the ester with the right stereochemistry is enantioselectively converted into escitalopram.
- an enantiomerically pure acid derivative such as (+) or (-)- ⁇ -methoxy- ⁇ - trifluoromethyl-phenylacetyl chloride
- the diol II is separated into the enantiomers by stereoselective crystallization with an enantiomerically pure acid such as (+)-di-p-toluoyltartaric acid, whereupon the S-enantiomer of the diol II is enantioselectively converted to escitalopram.
- an enantiomerically pure acid such as (+)-di-p-toluoyltartaric acid
- EP 563,388 discloses a simulated moving bed (SMB) chromatographic process wherein enantiomers of an optically active compound are separated and the stationary phase comprises silica gel coated with a chiral material such as a cellulose ester.
- SMB simulated moving bed
- the terms 'separation of enantiomers' and 'separation into enantiomers' refer to any process resulting in two or more fractions wherein the ratio between the two enantiomers deviates from 1:1.
- the term 'optically resolved' refers to the product of any such process.
- the term 'purity' means the purity of the enantiomer measured as percent enantiomeric excess (ee).
- 'carbohydrate derivative means any compound which principally can be derived from a carbohydrate by substitution of one or more hydroxyl groups with another substituent leaving the stereochemical structure intact.
- the terms 'intermediate for the manufacture of escitalopram' and 'intermediate compounds in the preparation of citalopram' means any intermediate in any known process for the manufacture of escitalopram.
- the present invention relates to a novel process for the preparation of escitalopram having the formula
- X is a cyano group, halogen or any other group which may be converted to a cyano group by optical resolution by chromatography of the racemic compound of formula
- citalopram is separated into its enantiomers by chromatography using a chiral stationary phase.
- the present invention relates to a novel process for the preparation of escitalopram having the formula
- the intermediate diol II 4-[4- (dimethylamino)- 1 -(4 ' -fluorophenyl)- 1 -hydroxy- 1 -butyl]-3-(hydroxymethyl)-benzo- nitrile is separated into its enantiomers by chromatography using a chiral stationary phase.
- the obtained (S)-4-[4-(dimethylamino)-l-(4'-fluorophenyl)-l-hydroxy-l- butyl]-3-(hydroxymethyl)-benzonitrile may be transformed into escitalopram by methods known to those skilled in the art, such as treatment with para- toluensulfonylchloride and a base, e.g. triethylamine, as disclosed in US 4,943,590.
- the invention also relates to the intermediate having the formula
- the present invention relates to the S-enantiomer of 5-Br- citalopram having the formula
- the racemic compounds of formula (V) and (VI) may be resolved by liquid chromatography or super or sub critical chromatography using a chiral stationary phase.
- the chiral stationary phase may comprise an optically active high molecular compound, e.g. a polysaccharide derivative, such as esters or carbamates of cellulose or amylose, a polyacrylate derivative (e.g. a methacrylate derivative, such as poly(triphenylmethylmethacrylate)) or a polyamide derivative, a protein with an asymmetric or disymmetric chain (bovine serum albumin bonded to silica, cellulase covalently bonded to aldehyde silica), polymers with an asymmetric centre in its side chains etc.
- a polysaccharide derivative such as esters or carbamates of cellulose or amylose
- a polyacrylate derivative e.g. a methacrylate derivative, such as poly(triphenylmethylmethacrylate)
- a chiral stationary phase comprising a low molecular compound having optical resolution capability, e.g. crown ethers ((S) or (R)-18-crown-6-ether on silica) and cyclodextrin derivatives (alpha cyclodextrin bonded to silica).
- chiral separation factors which may be comprised by the chiral stationary phase are amino acids and derivatives thereof, esters or amids of amino acids, acetylated amino acids and oligopeptides.
- a particulate polysaccharide material e.g microcrystalline cellulose triacetate.
- Chiral stationary phases including polysaccharide derivatives and polyamides useful for separation of enantiomers are described in EP 0 147 804, EP 0 155 637, EP 0 157 365, EP 0 238 044, WO 95/18833, WO 97/04011, EP 0656 333 and EP 718 625.
- the chiral stationary phase comprises a carbohydrate derivative, more preferred a polysaccharide derivative and most preferred an amylose or cellulose derivative.
- the polysaccharide adsorbed on the silica gel carry groups such as phenylcarbamoyl, 3,5-dimethyl-phenylcarbamoyl, 4-chlorophenylcarbamoyl, 3,5- dichloro-phenylcarbamoyl, acetyl, benzoyl, cinnamoyl, 4-methyl-benzoyl or S-alpha- phenylethyl carbamoyl.
- groups such as phenylcarbamoyl, 3,5-dimethyl-phenylcarbamoyl, 4-chlorophenylcarbamoyl, 3,5- dichloro-phenylcarbamoyl, acetyl, benzoyl, cinnamoyl, 4-methyl-benzoyl or S-alpha- phenylethyl carbamoyl.
- the carbohydrate derivative comprises phenyl carbamate substituents, which optionally may be substituted with one or more C,. 4 -alkyl groups, preferably methyl groups.
- the chiral compound which is the chiral separating factor of the stationary phase, may suitably be adsorbed on a carrier, such as silica gel.
- the chiral stationary phase is ChiralpakTM AD, a silica gel supported amylose derivative wherein the majority of the hydroxyl groups are substituted with 3,5- dimethylphenyl carbamate groups, or ChiralcelTM OD, a silica gel supported cellulose derivative wherein the majority of the hydroxyl groups are substituted with 3,5- dimethylphenyl carbamate groups.
- ChiralpakTM AD and ChiralcelTM OD are both obtainable from Daicel Chemical Industries Ltd.
- Chiral stationary phases comprising amylose phenyl carbamate derivatives are especially suitable for resolvation of compounds of formula (VI).
- exemplary of such chiral stationary phases is ChiralpakTM AD.
- Chiral stationary phases comprising cellulose phenyl carbamate derivatives are especially suitable for resolvation of compounds of formula (V).
- exemplary of such chiral stationary phases is ChiralcelTM OD.
- any liquid chromatographic separation method may be used for the separation of the enantiomers.
- the chromatographic separation method comprises a continuous chromatographic technology, suitably simulated moving bed technology.
- the eluent is typically selected from the group comprising acetonitrile, alcohols, such as methanol, ethanol or isopropanol, and alkanes, such as cyclohexane, hexane or heptane, and mixtures thereof.
- An acid such as formic acid, acetic acid and trifluoroacetic acid and/or a base such as diethylamine, triethylamine, propylamine, isopropylamine and dimethyl-isopropyl-amine may be added to the eluent.
- super or sub critical carbon dioxide containing a modifier may be used as eluent.
- the modifier is selected from lower alcohols such as methanol, ethanol, propanol and isopropanol.
- An amine such as diethylamine, triethylamine, propylamine, isopropylamine and dimethyl-isopropyl-amine and optionally an acid, such as formic acid, acetic acid and trifluoroacetic acid may be added.
- the chromatographic method used is a liquid chromatographic method.
- a suitable eluent according to this embodiment of the invention is acetonitrile.
- Another suitable eluent according to this embodiment of the invention is a mixture of iso-hexane and isopropanol.
- a suitable mixture contains iso-hexane 98% vol and isopropanol 2% 0 vol.
- Another suitable eluent according to the invention is super or sub critical carbon dioxide containing 10%> vol methanol with 0.5%> vol diethylamine and 0.5% vol trifluoroacetic acid.
- One embodiment of the invention comprises novel optically resolved intermediates for the manufacture of escitalopram.
- Z is OH in the compound of formula (VII)
- the alcohol group, Z may be converted to a suitable leaving group such as a sulfonate ester or a halide.
- the former is carried out by reaction with sulfonyl halides, such as methanesulfonyl chloride and p-toluensulfonyl chloride.
- halogenating agents such as thionyl chloride or phosphorus tribromide.
- Ring closure of the compounds of formula (VII), wherein Z is a leaving group, such as a sulfonate ester or halogen may thereafter be carried out by treatment with a base such as KOC(CH 3 ) 3 or other alkoxides, NaH or other hydrides, triethylamine, ethyldiisopropylamine or pyridine in an inert organic solvent, such as tetrahydrofuran, toluene, DMSO, DMF, t-butyl methyl ether, dimethoxyethane, dimethoxymethane, dioxane, acetonitrile or dichloromethane.
- a base such as KOC(CH 3 ) 3 or other alkoxides, NaH or other hydrides, triethylamine, ethyldiisopropylamine or pyridine
- an inert organic solvent such as tetrahydrofuran, toluene
- the ring closure is analogous to the process described in US 4,943,590.
- the compound of formula (IV) may be converted to escitalopram having the formula
- X in the compound of formula (IV) may be a cyano group, halogen, preferably chloro or bromo, or any other compound which may be converted to a cyano group.
- Such other groups, X, which may be converted to a cyano group may be selected from the groups of formula CF 3 -(CF 2 ) compassion-SO 2 -O- , wherein n is 0-8, -OH, -CHO, -CH 2 OH, - CH 2 NH 2 , -CH 2 NO 2 , -CH 2 C1, -CH 2 Br, -CH 3 , -NHR 1 , -COOR 2 , -CONR 2 R ⁇ wherein R 1 is hydrogen or alkylcarbonyl, and R 2 and R 3 are selected from hydrogen optionally substituted alkyl, aralkyl or aryl ,
- Y is O or S
- R 4 - R 5 are each independently selected from hydrogen and C,. 6 alkyl or R 4 and R 5 together form a C 2 _ 5 alkylene chain thereby forming a spiro ring;
- R 6 is selected from hydrogen and C,. 6 alkyl,
- R 7 is selected from hydrogen, C,. 6 alkyl, a carboxy group or a precursor group for a carboxy group, or R 6 and R 7 together form a C 2 . 5 alkylene chain thereby forming a spiro ring.
- conversion of the compound of formula (IV) to form escitalopram may be carried out according to the procedures described in US 4,136,193, WO 00/13648, WO 00/11926 and WO 01/02383 or other procedures suitable for such conversions.
- conversion of the 5-bromo group may be carried out by reaction of a compound of formula (IV) wherein X is bromo, with CuCN.
- WO 00/13648 and WO 00/11926 describes the conversion of a 5-halogen or a triflate group to a cyano group by cyanation with a cyanide source in presence of a Pd or Ni catalyst.
- the cyanide source used according to the catalysed cyanide exchange reaction may be any useful source.
- Preferred sources are KCN, NaCN or (R') 4 NCN, where (R') 4 indicates four groups which may be the same of different and are selected from hydrogen and straight chain or branched C,. 6 alkyl.
- the cyanide source is used in stoichiometric amount or in excess, preferably 1-2 equivalents are used pr. equivalent starting material.
- (R') 4 N + may conveniently be (Bu) 4 N + .
- the cyanide source is preferably NaCN or KCN or Zn(CN) 2 .
- the palladium catalyst may be any suitable Pd(0) or Pd(II) containing catalyst, such as Pd(PPh 3 ) 4 , Pd 2 (dba) 3 , Pd(PPh) 2 Cl 2 , etc.
- Pd catalyst is conveniently used in an amount of 1-10, preferably 2-6, most preferably about 4-5 mol%>.
- the reaction is carried out in the presence of a catalytic amount of Cu + or Zn 2+ .
- Catalytic amounts of Cu + and Zn 2+ respectively, means substoichiometric amounts such as 0.1 - 5, preferably 1 - 3 mol. Conveniently, about V ⁇ eq. is used per eq. Pd. Any convenient source of Cu + and Zn ++ may be used.
- Cu + is preferably used in the form of Cul, and Zn 2+ is conveniently used as the Zn(CN) 2 salt.
- cyanation is carried out by reaction with ZnCN 2 in the presence of a Palladium catalyst, preferably Pd(PPh 3 ) 4 (tetrakis(triphenylphos- phine)palladium) .
- a Palladium catalyst preferably Pd(PPh 3 ) 4 (tetrakis(triphenylphos- phine)palladium) .
- the nickel catalyst may be any suitable Ni(0) or Ni(II) containing complex which acts as a catalyst, such as Ni(PPh 3 ) 3 , ( ⁇ -aryl)-Ni(PPh 3 ) 2 Cl, etc.
- the nickel catalysts and their preparation are described in WO 96/11906, EP-A-613720 and EP-A-384392.
- the nickel(O) complex is prepared in situ before the cyanation reaction by reduction of a nickel(II) precursor such as NiCl 2 or NiBr 2 by a metal, such as zinc, magnesium or manganese in the presence of excess of complex ligands, preferably triphenylphosphin.
- a nickel(II) precursor such as NiCl 2 or NiBr 2
- a metal such as zinc, magnesium or manganese
- the Ni-catalyst is conveniently used in an amount of 0.5-10, preferably 2-6, most preferably about 4-5 mol%>. In one embodiment, the reaction is carried out in the presence of a catalytic amount of Cu + or Zn 2+ .
- Catalytic amounts of Cu + and Zn 2+ means substoichiometric amounts such as 0.1 - 5, preferably 1 - 3%>. Any convenient source of Cu + and Zn 2+ may be used.
- Cu + is preferably used in the form of Cul and Zn 2+ is conveniently used as the Zn(CN) 2 salt or formed in situ by reduction of a nickel (II) compounds using zinc.
- the cyanation reaction may be performed neat or in any convenient solvent, such solvent includes DMF, NMP, acetonitril, propionitrile, THF and ethylacetate.
- the cyanide exchange reaction may also be performed in an ionic liquid of the general formula (R") 4 N + , Y " , wherein R" are alkyl-groups or two of the R" groups together form a ring and Y " is the counterion.
- (R") 4 N + Y " represents
- the cyanide exchange reaction is conducted with apolar solvents such as benzene, xylene or mesitylene and under the influence of microwaves by using i.e. Synthewave 1000TM by Prolabo.
- the temperature ranges are dependent upon the reaction type. If no catalyst is present, preferred temperatures are in the range of 100-200 °C. When the reaction is conducted under the influence of microwaves, the temperature in the reaction mixture may raise to above 300 °C. More preferred temperature ranges are between 120-170 °C. The most preferred range is 130-150 °C.
- the preferred temperature range is between 0 and 100 °C. More preferred are temperature ranges of 40-90 °C. Most preferred temperature ranges are between 60-90 °C.
- Other reaction conditions, solvents, etc. are conventional conditions for such reactions and may easily be determined by a person skilled in the art.
- Another process for the conversion of a compound of formula (IV), wherein X is Br to the corresponding 5 -cyano derivative involves reaction of 5 -Br-citalopram of formula (IV) with magnesium to form a Grignard reagent, followed by reaction with a formamide to form an aldehyde.
- the aldehyde is converted to an oxime or a hydrazone which is converted to a cyano group by dehydration and oxidation, respectively.
- 5-Br-citalopram of formula (IV), wherein X is bromo may be reacted with magnesium to form a Grignard reagent, followed by reaction with a compound containing a CN group bound to a leaving group.
- Compounds of formula (IV), wherein the group X is a group of formula (X), may be converted to escitalopram by methods analogous to those described in WO 00/23431.
- Compounds of formula (IV), wherein X is OH, -CH 2 OH, -CH 2 NH 2 , -CH 2 NO 2 , -CH 2 C1, -CH 2 Br, -CH 3 and any of the other groups X above, may be converted to escitalopram by methods analogous to those prepared in WO 01/168632.
- the acid addition salts used according to the invention may be obtained by treatment of intermediates for the synthesis of escitalopram with the acid in a solvent followed by precipitation, isolation and optionally re-crystallisation by known methods and, if desired, micronisation of the crystalline product by wet or dry milling or another convenient process or preparation of particles from a solvent-emulsification process.
- a Novasep LicosepTM 10-50 Simulated Moving Bed Chromatograph was fitted with eight 50 mm i.d. columns each packed to a bed length of 15 cm with ChiralpakTM AD (20 ⁇ m) packing material using standard techniques.
- a SMB system of 8 columns in a 2-2-2-2 configuration was chosen for this separation.
- Acetonitrile (Baker HPLC grade) was used as mobile phase.
- the SMB operating conditions were: Temperature: 30 °C
- the obtained (S)-4- [4-(dimethylamino)- 1 -(4 ' -fluorophenyl)- 1 -hydroxy- 1 -butyl]-3 - (hydroxymethyl)-benzonitrile may be transformed into escitalopram by methods known to those skilled in the art, such as treatment with para-toluensulfonylchloride and a base, e.g. triethylamine, as disclosed in US 4,943,590.
- a column with the dimensions 280 x 110 mm packed with ChiralPak® (20 ⁇ m particle size) was used as the chiral stationary phase.
- a column with the dimensions 280 x 110 mm packed with Chiralcel ⁇ OD (20 ⁇ m particle size) was used as the chiral stationary phase.
- a mixture of 98%> vol isohexane and 2% vol isopropanol was used as the mobile phase.
- Both enantiomers were isolated from the eluent.
- the enantiomers were isolated with an enatiomeric excess of 86.1% (RT 3.25 min) and 87.1% (RT 3.67 min), respectively.
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0401451A HUP0401451A3 (en) | 2001-07-13 | 2002-07-12 | Method for preparation of escitalopram |
JP2003512221A JP2004538276A (en) | 2001-07-13 | 2002-07-12 | Manufacturing method of escitalopram |
EA200400177A EA014823B1 (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
IL15918302A IL159183A0 (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
BR0210817-8A BR0210817A (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram, and intermediate |
US10/483,824 US20050065207A1 (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
CA002451124A CA2451124C (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
MEP-20/08A MEP2008A (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
MXPA04000205A MXPA04000205A (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram. |
EP02750836A EP1409472A1 (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
YU1804A RS1804A (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
KR1020047000502A KR100956260B1 (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
UA20031211985A UA84258C2 (en) | 2001-07-13 | 2002-12-07 | Method for the preparation of escitalopram |
IS7064A IS7064A (en) | 2001-07-13 | 2003-12-04 | Process for the production of acitalopram |
HR20031074A HRPK20031074B3 (en) | 2001-07-13 | 2003-12-23 | Method for the preparation of escitalopram |
NO20040027A NO328561B1 (en) | 2001-07-13 | 2004-01-05 | Process for the preparation of escitalopram, and intermediates thereof. |
HK05101842.3A HK1069386A1 (en) | 2001-07-13 | 2005-03-02 | Method for the preparation of escitalopram |
US12/781,048 US20110065938A1 (en) | 2001-07-13 | 2010-05-17 | Method for the preparation of escitalopram |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101101 | 2001-07-13 | ||
DKPA200101101 | 2001-07-13 | ||
DKPA200101852 | 2001-12-11 | ||
DKPA200101851 | 2001-12-11 | ||
DKPA200101851 | 2001-12-11 | ||
DKPA200101852 | 2001-12-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/483,824 A-371-Of-International US20050065207A1 (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
US12/781,048 Continuation US20110065938A1 (en) | 2001-07-13 | 2010-05-17 | Method for the preparation of escitalopram |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003006449A1 true WO2003006449A1 (en) | 2003-01-23 |
Family
ID=27222518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2002/000491 WO2003006449A1 (en) | 2001-07-13 | 2002-07-12 | Method for the preparation of escitalopram |
Country Status (29)
Country | Link |
---|---|
US (2) | US20050065207A1 (en) |
EP (1) | EP1409472A1 (en) |
JP (1) | JP2004538276A (en) |
KR (4) | KR20080108629A (en) |
CN (2) | CN101265199A (en) |
AR (1) | AR034759A1 (en) |
AU (1) | AU2009200448A1 (en) |
BG (1) | BG108572A (en) |
BR (1) | BR0210817A (en) |
CA (1) | CA2451124C (en) |
CO (1) | CO5550496A2 (en) |
EA (1) | EA014823B1 (en) |
HK (1) | HK1069386A1 (en) |
HR (1) | HRPK20031074B3 (en) |
HU (1) | HUP0401451A3 (en) |
IL (1) | IL159183A0 (en) |
IS (1) | IS7064A (en) |
ME (1) | MEP2008A (en) |
MX (1) | MXPA04000205A (en) |
MY (1) | MY144333A (en) |
NO (1) | NO328561B1 (en) |
PE (1) | PE20030253A1 (en) |
PL (1) | PL366383A1 (en) |
RS (1) | RS1804A (en) |
TW (1) | TWI268926B (en) |
UA (1) | UA84258C2 (en) |
UY (1) | UY27379A1 (en) |
WO (1) | WO2003006449A1 (en) |
ZA (1) | ZA200309471B (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014821A1 (en) | 2002-08-12 | 2004-02-19 | H. Lundbeck A/S | Method for the separation of intermediates which may be used for the preparation of escitalopram |
ES2228274A1 (en) * | 2003-09-24 | 2005-04-01 | Astur Pharma, S.A. | Enzymatic synthesis of citalopram derivative comprises diol treatment with acylating agent in presence of Candida antarctica lipase |
WO2006001494A1 (en) * | 2004-06-25 | 2006-01-05 | Sumitomo Chemical Company, Limited | Process for producing optically active citalopram, intermediate therefor, and process for producing the same |
WO2006037714A3 (en) * | 2004-10-01 | 2006-07-27 | Adorkem Technology Spa | Process for the preparation of citalopram and escitalopram |
JP2006522753A (en) * | 2003-04-10 | 2006-10-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Method for cleaving amines useful in the treatment of diseases associated with insulin resistance syndrome |
WO2006106531A1 (en) * | 2005-04-04 | 2006-10-12 | Jubilant Organosys Ltd | Process for the preparation of escitalopram or its acid addition salts |
WO2006136169A2 (en) | 2005-06-22 | 2006-12-28 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
WO2007054105A2 (en) * | 2005-11-14 | 2007-05-18 | H. Lundbeck A/S | Method for the preparation of escitalopram |
WO2007082771A1 (en) | 2006-01-23 | 2007-07-26 | Sandoz Ag | Carbonyl asymmetric alkylation |
US7420068B2 (en) | 2004-03-05 | 2008-09-02 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
EP1988086A1 (en) | 2007-04-23 | 2008-11-05 | Synthon B.V. | Process for resolving citalopram via its (S)-enriched citalopram tartrate compound. |
US7470526B2 (en) | 2004-04-09 | 2008-12-30 | Adorken Technology Spa | Chemo-enzymatic process for the preparation of escitalopram |
EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
WO2009033488A1 (en) | 2007-09-11 | 2009-03-19 | H. Lundbeck A/S | Method for manufacture of escitalopram |
US7560576B2 (en) | 2005-06-22 | 2009-07-14 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US7569605B2 (en) | 2005-10-14 | 2009-08-04 | Forest Laboratories Holdings Limited | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
EP2363389A1 (en) | 2002-12-23 | 2011-09-07 | H. Lundbeck A/S | A process for the preparation of racemic citalopram diol and/or S- or R-citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram |
US8022232B2 (en) | 2007-09-11 | 2011-09-20 | H. Lundbeck A/S | Method for manufacture of escitalopram |
CN106568863A (en) * | 2016-11-04 | 2017-04-19 | 北京万全德众医药生物技术有限公司 | Method for separating and determining escitalopram oxalate intermediate and optical isomer thereof by using high-performance liquid chromatography |
CN107941962A (en) * | 2017-12-28 | 2018-04-20 | 北京和合医学诊断技术股份有限公司 | Detect the liquid phase chromatography analytical method of escitalopram medicament contg in blood |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI339651B (en) * | 2004-02-12 | 2011-04-01 | Lundbeck & Co As H | Method for the separation of intermediates which may be used for the preparation of escitalopram |
US7989645B2 (en) * | 2004-08-23 | 2011-08-02 | Sun Pharma Global Fze | Process for preparation of citalopram and enantiomers |
WO2006021971A2 (en) | 2004-08-23 | 2006-03-02 | Sun Pharmaceutical Industries Limited | 'process for preparation of citalopram and enantiomers' |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136193A (en) * | 1976-01-14 | 1979-01-23 | Kefalas A/S | Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans |
US4943590A (en) * | 1988-06-14 | 1990-07-24 | H. Lundbeck A/S | Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof |
WO2001043525A2 (en) * | 2000-02-24 | 2001-06-21 | H. Lundbeck A/S | Method for the preparation of citalopram |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
JP3010816B2 (en) * | 1991-08-22 | 2000-02-21 | ダイセル化学工業株式会社 | Method for recovering optical isomer and solvent in optical resolution, method for recycling solvent, and method for reusing optical isomer |
US5514818A (en) * | 1993-09-17 | 1996-05-07 | Daicel Chemical Industries, Ltd. | Resolution of stereoisomers of aliphatic epoxides |
US5889180A (en) * | 1997-11-10 | 1999-03-30 | Uop Llc | Use of small pore silicas as a support for a chiral stationary phase |
US6967259B2 (en) * | 2001-09-24 | 2005-11-22 | Pharmachem Technologies Limited | Process for the preparation of Citalopram intermediate |
US6764200B1 (en) * | 2003-01-15 | 2004-07-20 | Hsiang Lan Wu Liu | Decorative lantern |
-
2002
- 2002-07-10 AR ARP020102574A patent/AR034759A1/en not_active Application Discontinuation
- 2002-07-11 TW TW091115430A patent/TWI268926B/en not_active IP Right Cessation
- 2002-07-11 PE PE2002000617A patent/PE20030253A1/en not_active Application Discontinuation
- 2002-07-12 EA EA200400177A patent/EA014823B1/en not_active IP Right Cessation
- 2002-07-12 CA CA002451124A patent/CA2451124C/en not_active Expired - Fee Related
- 2002-07-12 PL PL02366383A patent/PL366383A1/en unknown
- 2002-07-12 IL IL15918302A patent/IL159183A0/en unknown
- 2002-07-12 UY UY27379A patent/UY27379A1/en not_active Application Discontinuation
- 2002-07-12 KR KR1020087029127A patent/KR20080108629A/en not_active Application Discontinuation
- 2002-07-12 CN CNA2008100930541A patent/CN101265199A/en active Pending
- 2002-07-12 MX MXPA04000205A patent/MXPA04000205A/en active IP Right Grant
- 2002-07-12 HU HU0401451A patent/HUP0401451A3/en unknown
- 2002-07-12 ME MEP-20/08A patent/MEP2008A/en unknown
- 2002-07-12 CN CNB028139984A patent/CN100457746C/en not_active Expired - Lifetime
- 2002-07-12 EP EP02750836A patent/EP1409472A1/en not_active Withdrawn
- 2002-07-12 RS YU1804A patent/RS1804A/en unknown
- 2002-07-12 KR KR1020047000502A patent/KR100956260B1/en not_active IP Right Cessation
- 2002-07-12 US US10/483,824 patent/US20050065207A1/en not_active Abandoned
- 2002-07-12 WO PCT/DK2002/000491 patent/WO2003006449A1/en active Application Filing
- 2002-07-12 KR KR1020107004689A patent/KR20100036387A/en not_active Application Discontinuation
- 2002-07-12 BR BR0210817-8A patent/BR0210817A/en not_active Application Discontinuation
- 2002-07-12 KR KR1020087029126A patent/KR20080108628A/en not_active Application Discontinuation
- 2002-07-12 JP JP2003512221A patent/JP2004538276A/en active Pending
- 2002-07-13 MY MYPI20022664A patent/MY144333A/en unknown
- 2002-12-07 UA UA20031211985A patent/UA84258C2/en unknown
-
2003
- 2003-12-04 IS IS7064A patent/IS7064A/en unknown
- 2003-12-05 ZA ZA200309471A patent/ZA200309471B/en unknown
- 2003-12-23 HR HR20031074A patent/HRPK20031074B3/en not_active IP Right Cessation
-
2004
- 2004-01-05 NO NO20040027A patent/NO328561B1/en not_active IP Right Cessation
- 2004-02-04 CO CO04008776A patent/CO5550496A2/en not_active Application Discontinuation
- 2004-02-09 BG BG108572A patent/BG108572A/en unknown
-
2005
- 2005-03-02 HK HK05101842.3A patent/HK1069386A1/en not_active IP Right Cessation
-
2009
- 2009-02-06 AU AU2009200448A patent/AU2009200448A1/en not_active Abandoned
-
2010
- 2010-05-17 US US12/781,048 patent/US20110065938A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136193A (en) * | 1976-01-14 | 1979-01-23 | Kefalas A/S | Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans |
US4943590A (en) * | 1988-06-14 | 1990-07-24 | H. Lundbeck A/S | Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof |
WO2001043525A2 (en) * | 2000-02-24 | 2001-06-21 | H. Lundbeck A/S | Method for the preparation of citalopram |
Non-Patent Citations (3)
Title |
---|
"Separation of enantiomers by chiral chromatography/chiral HPL", CHROMTECH, XP002961853, Retrieved from the Internet <URL:http://www.chromtech.se/> [retrieved on 20021029] * |
CARLSSON B. ET AL.: "Characterization of the chiral separation of citalopram and its demethylated metabolites by response-surface methodology", CHROMATOGRAPHIA. AN INTERNATIONAL JOURNAL FOR RAPID COMMUNICATION IN CHROMATOGRAPHY, ELECTROPHORESIS AND ASSOCIATED TECHNIQUES, vol. 53, March 2001 (2001-03-01), pages ABSTRACT 266, XP002961852, Retrieved from the Internet <URL:http://www.chromatographia.de/chroma/daten/march_53_abstracts.htm> [retrieved on 20021028] * |
HAUPT DAN: "Determination of citalopram enantiomers in human plasma by liquid chromatographic separation on a chiral-AGP column", JOURNAL OF CHROMATOGRAPHY B, vol. 685, 1996, pages 299 - 305, XP004069840 * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA011762B1 (en) * | 2002-08-12 | 2009-06-30 | Х. Лундбекк А/С | Method for the separation of intermediates which may be used for the preparation of escitalopram |
EP2360150A1 (en) | 2002-08-12 | 2011-08-24 | H. Lundbeck A/S | Method for the separation of intermediates which may be used for the preparation of escitalopram |
US8067640B2 (en) | 2002-08-12 | 2011-11-29 | H. Lundbeck A/S | Method for the separation of intermediates which may be used for the preparation of escitalopram |
WO2004014821A1 (en) | 2002-08-12 | 2004-02-19 | H. Lundbeck A/S | Method for the separation of intermediates which may be used for the preparation of escitalopram |
EP2363389A1 (en) | 2002-12-23 | 2011-09-07 | H. Lundbeck A/S | A process for the preparation of racemic citalopram diol and/or S- or R-citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram |
JP2006522753A (en) * | 2003-04-10 | 2006-10-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Method for cleaving amines useful in the treatment of diseases associated with insulin resistance syndrome |
JP4836778B2 (en) * | 2003-04-10 | 2011-12-14 | ポクセル ソシエテ パール アクシオン サンプリフィエ | Method for cleaving amines useful in the treatment of diseases associated with insulin resistance syndrome |
ES2228274A1 (en) * | 2003-09-24 | 2005-04-01 | Astur Pharma, S.A. | Enzymatic synthesis of citalopram derivative comprises diol treatment with acylating agent in presence of Candida antarctica lipase |
US7420068B2 (en) | 2004-03-05 | 2008-09-02 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
US7470526B2 (en) | 2004-04-09 | 2008-12-30 | Adorken Technology Spa | Chemo-enzymatic process for the preparation of escitalopram |
WO2006001494A1 (en) * | 2004-06-25 | 2006-01-05 | Sumitomo Chemical Company, Limited | Process for producing optically active citalopram, intermediate therefor, and process for producing the same |
US7482477B2 (en) | 2004-10-01 | 2009-01-27 | Adorkem Technology Spa | Process for the preparation of citalopram and escitalopram |
JP2008514670A (en) * | 2004-10-01 | 2008-05-08 | エイドルケム テクノロジー エスピーエー | Preparation method of citalopram and escitalopram |
WO2006037714A3 (en) * | 2004-10-01 | 2006-07-27 | Adorkem Technology Spa | Process for the preparation of citalopram and escitalopram |
WO2006106531A1 (en) * | 2005-04-04 | 2006-10-12 | Jubilant Organosys Ltd | Process for the preparation of escitalopram or its acid addition salts |
EP2385044A1 (en) | 2005-06-22 | 2011-11-09 | H. Lundbeck A/S | Orodispersible tablet and process for preparing the same |
WO2006136169A2 (en) | 2005-06-22 | 2006-12-28 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US7723533B2 (en) | 2005-06-22 | 2010-05-25 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
EP2325177A1 (en) | 2005-06-22 | 2011-05-25 | H. Lundbeck A/S | Crystalline base of escitalopram |
BG66086B1 (en) * | 2005-06-22 | 2011-03-31 | H. Lundbeck A/S | Crystalline base of escitalopram |
US7560576B2 (en) | 2005-06-22 | 2009-07-14 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US7569605B2 (en) | 2005-10-14 | 2009-08-04 | Forest Laboratories Holdings Limited | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
WO2007054105A3 (en) * | 2005-11-14 | 2007-11-08 | Lundbeck & Co As H | Method for the preparation of escitalopram |
WO2007054105A2 (en) * | 2005-11-14 | 2007-05-18 | H. Lundbeck A/S | Method for the preparation of escitalopram |
US8288569B2 (en) | 2006-01-23 | 2012-10-16 | Sandoz Ag | Carbonyl asymmetric alkylation |
WO2007082771A1 (en) | 2006-01-23 | 2007-07-26 | Sandoz Ag | Carbonyl asymmetric alkylation |
EP1988086A1 (en) | 2007-04-23 | 2008-11-05 | Synthon B.V. | Process for resolving citalopram via its (S)-enriched citalopram tartrate compound. |
US7566793B2 (en) | 2007-04-23 | 2009-07-28 | Synthon Bv | Process for resolving citalopram |
EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
DE102008046530A1 (en) | 2007-09-11 | 2009-03-19 | H. Lundbeck A/S, Valby | Process for the preparation of escitalopram |
US8022232B2 (en) | 2007-09-11 | 2011-09-20 | H. Lundbeck A/S | Method for manufacture of escitalopram |
WO2009033488A1 (en) | 2007-09-11 | 2009-03-19 | H. Lundbeck A/S | Method for manufacture of escitalopram |
EA012787B1 (en) * | 2007-09-11 | 2009-12-30 | Х. Лундбекк А/С | Method for the preparation of escitalopram |
EP2397461A1 (en) | 2007-09-11 | 2011-12-21 | H. Lundbeck A/S | Method for the manufacture of escitalopram |
LT5577B (en) | 2007-09-11 | 2009-06-25 | H. Lundbeck A/S | Method for manufacture of escitalopram |
CN106568863A (en) * | 2016-11-04 | 2017-04-19 | 北京万全德众医药生物技术有限公司 | Method for separating and determining escitalopram oxalate intermediate and optical isomer thereof by using high-performance liquid chromatography |
CN107941962A (en) * | 2017-12-28 | 2018-04-20 | 北京和合医学诊断技术股份有限公司 | Detect the liquid phase chromatography analytical method of escitalopram medicament contg in blood |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110065938A1 (en) | Method for the preparation of escitalopram | |
Zhong et al. | New β-amino alcohols with a bicyclo [3.3. 0] octane scaffold in an asymmetric Henry reaction | |
Touge et al. | Multiple absolute stereocontrol in cascade lactone formation via dynamic kinetic resolution driven by the asymmetric transfer hydrogenation of keto acids with Oxo-tethered ruthenium catalysts | |
Prakash et al. | Investigation of the enantioselective synthesis of 2, 3-dihydroquinazolinones using Sc (III)–inda-pybox | |
US20050154051A1 (en) | Method for the preparation of escitalopram | |
Raimondi et al. | Activation of 1, 2-and 1, 3-ketoamides with thiourea organocatalyst for the enantioselective domino synthesis of functionalized cyclohexanes | |
WO1993006111A2 (en) | A chiral selector useful for separation of enantiomers of beta-amino alcohol compounds | |
Roos et al. | Synthesis of novel C2-symmetric ligands based on (R, R)-and (S, S)-diphenyl-1, 3-propanediol | |
EP1268584B1 (en) | Compositions and methods for selectively binding amines or amino acid enantiomers over their counter-enantiomers | |
AU2002354525A1 (en) | Method for the preparation of escitalopram | |
CN106008328B (en) | The preparation of the disubstituted-β-nitro ester type compound of α containing full carbon quaternary carbon chiral centre and nitrogen aromatic heterocycle, α-and its derivative | |
Blaser et al. | Ethyl 2, 4-dioxo-4-phenylbutyrate: a versatile intermediate for the large-scale preparation of enantiomerically pure α-hydroxy and α-amino acid esters | |
JP2001526111A (en) | Catalyst compositions based on chiral ligands having molybdenum, tungsten or chromium and methods for asymmetric alkylation of allylic substrates | |
Oi et al. | Chiral stationary phases consisting of axially dissymmetric 2′-substituted-1, 1′-binaphthyl-2-carboxylic acids bonded to silica gel for high-performance liquid chromatographic separation of enantiomers | |
WO2021002407A1 (en) | Fluoroalkyl group-containing compound and production method therefor | |
KR100390765B1 (en) | Process for preparing (-)-(18-Crown-6)-2,3,11,12-tetracarboxylic acid, and (-)-chiral stationary phases for resolution of racemic compounds using the same | |
KR100392710B1 (en) | Method for preparing of chiral compound by asymmetric ring opening reactions of epoxides | |
JP2001213864A (en) | Method for separating isomers of lactam isomer mixture and use of optical antipode obtained thereby | |
WO1996027581A1 (en) | Enantioselective synthesis of cyclic amino alcohols | |
JPH07242653A (en) | Separation of optical isomer of imidazole derivative | |
JPH0253781A (en) | Oxazolinecarboxamide derivative and production thereof | |
HRP20020571A2 (en) | Method for preparation of enantiomere free atenolol using preparative chromatography on chiral static phase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-18/04 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1-2003-501276 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 159183 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/09471 Country of ref document: ZA Ref document number: 200309471 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 530014 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2451124 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PK20031074A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/000205 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003512221 Country of ref document: JP Ref document number: 2002750836 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028139984 Country of ref document: CN Ref document number: 2002354525 Country of ref document: AU Ref document number: 1020047000502 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 10857202 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 108572 Country of ref document: BG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 293/CHENP/2004 Country of ref document: IN Ref document number: 200400177 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200400127 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002750836 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10483824 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002750836 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087029126 Country of ref document: KR Ref document number: 1020087029127 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020107004689 Country of ref document: KR |